LLY-507

Research use only, not for human use.

A potent, selective and cell-active inhibitor of SMYD2 (IC50<15 nM).

A potent, selective and cell-active inhibitor of SMYD2 (IC50<15 nM); displays >100-fold selective over a broad range of methyltransferase and non-methyltransferase targets; inhibits SMYD2-mediated methylation of p53 Lys370 and suppresses proliferation of several esophageal, liver, and breast cancer cell lines in a dose-dependent manner (IC50=1.5-6 uM).

Cell Proliferation Assay Cell Line:ESCC, HCC, breast cancer cell lines Concentration:0-20 μM Incubation Time:3 days, 7 days Result:Inhibited tumor cell proliferation.Western Blot Analysis Cell Line:HEK293 cells Concentration:0.03 μM, 0.07 μM, 0.15 μM, 0.3 μM, 0.6 μM, 1.25 μM, 2.5 μM Incubation Time:28 hours Result:Inhibited SMYD2-mediated methylation of p53 Lys370 in cells.

——

LLY-507 | LLY 507 | LLY507

Chromatin/Epigenetic

HMTase

SMYD2

Cancer

——

1793053-37-8

574.7583

C36H42N6O

>98% (HPLC)

DMSO: 15 mg/mL

O=C(C1=CC(C2=CC=CC=C2N3CCN(CCN4C=C(C)C5=C4C=CC=C5)CC3)=CC(C#N)=C1)NCCCN6CCCC6

[1,1'-Biphenyl]-3-carboxamide, 5-cyano-2'-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]-1-piperazinyl]-N-[3-(1-pyrrolidinyl)propyl]-

(-20℃)

With Ice Pack

≥ 2 years